Key Takeaways
- • The FDA issued a Request for Information (RFI) on March 31, 2026, seeking public feedback on the integration of digital health technologies (DHTs) in clinical drug and biological product investigations, signaling regulatory expansion in this sector.
- • DHTs encompassing wearables, implantables, ingestibles, and contactless sensors—many integrated into smartphones and smartwatches—are advancing capabilities for remote health data collection, interactive clinical assessments, and neuropsychiatric function measurement in clinical trials.
- • The RFI represents the FDA's continued commitment under PDUFA VII reauthorization (2022) to support DHT adoption, building on prior guidance issued in March 2023 (Framework for DHTs) and December 2023 (remote data acquisition guidance).
- • Emerging pediatric-focused DHT applications, including gamified clinical testing tools, represent expanding opportunities for innovation in clinical investigation design and patient engagement.
- • The FDA is actively soliciting stakeholder input to identify opportunities and challenges in DHT integration, suggesting potential future regulatory guidance or policy clarifications that could impact pharmaceutical development timelines and trial design strategies.
Summary
Digital health technologies, as defined by the FDA in this RFI, encompass remote health data collection platforms utilizing computing infrastructure, connectivity, software, and sensors. These include wearable devices (smartwatches, patches), implantable technologies, ingestible sensors, and contactless systems. Many DHTs are already embedded in consumer devices and can be customized through mobile applications. The FDA specifically noted that DHTs support diverse clinical assessment functions, ranging from physical measurements such as strength, coordination, and balance to neuropsychiatric evaluations including reaction time, cognition, and sensory processing capabilities.
The RFI builds on a regulatory foundation established under the Prescription Drug User Fee Act (PDUFA) reauthorization in 2022. The FDA previously published a Framework for the Use of DHTs in Drug and Biological Product Development in March 2023, followed by December 2023 guidance on Digital Health Technologies for Remote Data Acquisition in Clinical Investigations. These prior actions established the agency's commitment to supporting appropriate DHT integration while maintaining scientific rigor and data integrity standards in clinical trial design.
Notably, the FDA highlighted emerging opportunities for pediatric-focused DHT applications, including gamified clinical testing platforms designed to engage children in investigational assessments. The agency's request for broader stakeholder input suggests the organization is identifying both opportunities and regulatory challenges that require clarification or additional guidance. For institutional investors and pharmaceutical companies, this RFI indicates the FDA's openness to technology-driven trial innovations while signaling that formal regulatory pathways and expectations for DHT validation, data security, and clinical utility may be forthcoming.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.